Patricia M Danzon
Overview
Explore the profile of Patricia M Danzon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamal-Bahl S, Towse A, Spurgin L, Danzon P
Value Health
. 2019 Jun;
22(6S):S24-S28.
PMID: 31200803
No abstract available.
2.
Danzon P
Recent Results Cancer Res
. 2018 Dec;
213:153-167.
PMID: 30543012
This paper first reviews the evidence on price levels, price growth, and value for cancer drugs. The available evidence suggests that prices for originator (brand-name) drugs are rising significantly more...
3.
Danzon P
Pharmacoeconomics
. 2018 Aug;
36(12):1395-1405.
PMID: 30062518
Differential pricing-manufacturers varying prices for on-patent pharmaceuticals across markets-can, in theory, lead to increased patient access and improved research and development (R&D) incentives compared with charging a uniform price across...
4.
Danzon P
Value Health
. 2018 Mar;
21(3):252-257.
PMID: 29566830
Objectives: To analyze how value-based pricing (VBP), which grounds the price paid for pharmaceuticals in their value, can manage "affordability" challenges, defined as drugs that meet cost-effectiveness thresholds but are...
5.
Garrison Jr L, Neumann P, Willke R, Basu A, Danzon P, Doshi J, et al.
Value Health
. 2018 Feb;
21(2):161-165.
PMID: 29477394
This summary section first lists key points from each of the six sections of the report, followed by six key recommendations. The Special Task Force chose to take a health...
6.
Phelps C, Lakdawalla D, Basu A, Drummond M, Towse A, Danzon P
Value Health
. 2018 Feb;
21(2):146-154.
PMID: 29477392
The fifth section of our Special Task Force report identifies and discusses two aggregation issues: 1) aggregation of cost and benefit information across individuals to a population level for benefit...
7.
Danzon P, Drummond M, Towse A, Pauly M
Value Health
. 2018 Feb;
21(2):140-145.
PMID: 29477391
The fourth section of our Special Task Force report focuses on a health plan or payer's technology adoption or reimbursement decision, given the array of technologies, on the basis of...
8.
Lakdawalla D, Doshi J, Garrison Jr L, Phelps C, Basu A, Danzon P
Value Health
. 2018 Feb;
21(2):131-139.
PMID: 29477390
The third section of our Special Task Force report identifies and defines a series of elements that warrant consideration in value assessments of medical technologies. We aim to broaden the...
9.
Danzon P, Mulcahy A, Towse A
Health Econ
. 2013 Dec;
24(2):238-52.
PMID: 24293058
This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across countries. We focus on drugs to treat HIV/AIDS, TB, and malaria in middle and low-income countries (MLICs),...
10.
Danzon P, Epstein A
Adv Health Econ Health Serv Res
. 2012 Nov;
23:35-71.
PMID: 23156660
Purpose: This study examines the effect of price regulation and competition on launch timing and pricing of new drugs. Methods: Our data cover launch experience in 15 countries from 1992...